Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that its wholly-owned immunotherapeutics subsidiary, Antigen...
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that it has entered into a non-binding Letter of Intent (LOI) with...
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it has entered into a non-binding Letter of Intent (LOI) with...
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced the issuance of a white paper on the use of cannabis for medicinal...
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that research and development work on buccal Leuprolide has begun....
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that its previously announced intention to implement a buccal...
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced the issuance of a white paper on the status of Generex Oral-lyn™,...
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today provided an update on the status of the buccal insulin formulation...
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that it entered into a securities purchase agreement with an...
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that it has entered into a Memorandum of Understanding with...
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) announced today that updated data from the on-going Phase II clinical trial of the...
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it intends to dividend to its stockholders a portion of the...
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that it has entered into a non-binding Letter of Intent (LOI) to...
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) announced today presentation of data from the on-going Phase II clinical trial of...
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced the resignation of John P. Barratt as a member of the Company's...
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that results of the last pre-specified analysis of data from a...
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced its participation in a MedCannAccess (www.MedCannAccess.com)...
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that it has entered into a non-binding Letter of Intent (LOI) to...
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced a presentation showing that induction of an antibody response to...
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced two presentations demonstrating that the extent of the...
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that the Company's wholly-owned subsidiary, Antigen Express, Inc....
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that its wholly owned subsidiary, Antigen Express, Inc....
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today responded to a recent article posted to the Seeking Alpha website...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.